Equity Research Analyst’s Stock Ratings: Milestone Scientific Inc. (MLSS), INSYS Therapeutics, Inc. (INSY)

Milestone Scientific Inc. (NYSE:MLSS) tinted gains of +7.36% (+0.03 points) to US$0.38. The volume of 0.41 Million shares climbed down over an trading activity of 178.4 Million shares. EPS ratio determined by looking at last 12 month figures is -0.27. Over the same time span, the stock marked US$1.1 as its best level and the lowest price reached was US$0.26. The corporation has a market cap of US$12.97 Million.

Milestone Scientific Inc. (NYSE:MLSS)’s earnings per share has been growing at a -24 percent rate over the past 5 year when average revenue increase was noted as 5.5 percent. The return on equity ratio or ROE stands at -198.4 percent while most common profitability ratio return on investment (ROI) was -73 percent. The company’s institutional ownership is monitored at 7 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 46.5 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 2. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

INSYS Therapeutics, Inc. (NASDAQ:INSY) is worth US$324.88 Million and has recently risen 7.3% to US$4.41. The latest exchange of 1.44 Million shares is below its average trading activity of 736.69 Million shares. The day began at US$4.06 but the price moved to US$4.06 at one point during the trading and finally capitulating to a session high of US$4.4. The stock tapped a 52-week high of US$11.65 while the mean 12-month price target for the shares is US$8.5.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0, and a price to sales ratio of 3.34. For the past 5 years, the company’s revenue has grown 55.5%, while the company’s earnings per share has grown -28.5%. With an institutional ownership near 22%, it carries an earnings per share ratio of -1.6.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 1 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.